Phase 1 Ovarian Cancer Trial, Recruiting NCT04701645 Sponsor: Brigham and Women's Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT04701645
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a suspected or confirmed diagnosis of advanced ovarian, fallopian tube, or peritoneal cancer (stage III or IV, meaning the cancer has spread outside the pelvis).
  • You fall into one of these four groups:
    • You are newly diagnosed (or suspected) and your doctor has recommended surgery to remove the cancer, but you have not had surgery yet.
    • You are newly diagnosed and your doctor needs to perform a keyhole (laparoscopic) procedure to decide whether surgery or chemotherapy first is the right approach for you.
    • Your ovarian cancer has come back and your doctor is considering surgery to remove it or confirm the recurrence.
    • You have already had chemotherapy before surgery (called neoadjuvant chemotherapy) and your doctor has now recommended surgery, but you have not had it yet.
  • You are 18 years of age or older.
  • Your doctors (cancer surgeon and medical oncologist) consider you healthy enough to safely have both a needle procedure and your planned surgery.
  • Your recent blood test results (taken within 14 days before the study procedure, or 7 days if you are in group 4 above) meet certain safety levels for blood counts and clotting ability.
  • If you could become pregnant, you must have a negative pregnancy test before joining.
  • You have had a CT scan of your abdomen and pelvis within the past 4 weeks that shows enough detail about your cancer and confirms a safe location for the study device to be placed and later removed during surgery.
  • Your tumour is large enough for the study device to be safely placed inside it, without affecting the tissue needed for your diagnosis.
  • The tumour where the device will be placed can be safely reached by a needle from outside the body, and can be removed during your planned surgery or keyhole procedure without significantly affecting the operation or your safety.
  • You are willing and able to understand and sign a consent form.
  • You are willing to have research genetic testing (of both your tumour and inherited genes) and agree to your anonymised genetic data being stored in a national health research database.

Who may not be able to join:

  • You have a serious uncontrolled illness, such as an active infection, unstable heart condition, irregular heartbeat, or a mental health or personal situation that would make a biopsy or surgery unsafe.
  • You are currently pregnant, due to the radiation involved in imaging and the potential risks of the needle procedure near the baby.
  • You have a bleeding or clotting disorder that cannot be corrected and that increases the risk of a needle biopsy or surgery.
  • You have significant health risk factors (such as a high risk of blood clots, stroke, or heart attack) that mean it would not be safe for you to stop blood-thinning medication before the procedure, according to standard medical guidelines. (Note: taking low-dose aspirin alone does not disqualify you.)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Elizabeth Stover, MD, PhD, Dana-Farber Cancer Institute

Phone: (617) 632-5269

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
5 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with adverse events as defined in the CTCAE v5.0; Number of implanted microdevices successfully retrieved

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov